Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

EPILEPSY

How safe is switching antiepileptic drug manufacturers?

Nature Reviews Neurology volume 15, pages 8–9 (2019)Cite this article

Subjects

A nationwide German study of prescription data has demonstrated that switching to an antiepileptic drug from a different manufacturer increases the risk of seizure relapse. This finding sparks a debate about the reason for seizure worsening after switching and whether or not it is a pharmacological issue.

Refers to Lang, J. D. et al. Switching the manufacturer of anti-epileptic drugs is associated with higher risk of seizures. Ann. Neurol. https://doi.org/10.1002/ana.25353 (2018).

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Lang, J. D. et al. Switching the manufacturer of anti-epileptic drugs is associated with higher risk of seizures. Ann. Neurol. https://doi.org/10.1002/ana.25353 (2018).

    Article  PubMed  Google Scholar 

  2. Davit, B. M. et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann. Pharmacother. 43, 1583–1597 (2009).

    CAS  Article  Google Scholar 

  3. Krauss, G. L. et al. Assessing bioequivalence of generic antiepilepsy drugs. Ann. Neurol. 70, 221–228 (2011).

    CAS  Article  Google Scholar 

  4. Labiner, D. M. et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 74, 1566–1574 (2010).

    CAS  Article  Google Scholar 

  5. Andermann, F. et al. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48, 464–469 (2007).

    CAS  Article  Google Scholar 

  6. Ting, T. J. et al. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard. Epilepsia 56, 1415–1424 (2015).

    CAS  Article  Google Scholar 

  7. Privitera, M. D. et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurol. 15, 365–372 (2016).

    CAS  Article  Google Scholar 

  8. Gollwitzer, S. et al. Nonadherence to antiepileptic drugs in Germany: a retrospective, population-based study. Neurology 87, 466–472 (2016).

    CAS  Article  Google Scholar 

  9. Kesselheim, A. S. et al. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern. Med. 173, 202–208 (2013).

    Article  Google Scholar 

  10. Holtkamp, M. & Theodore, W. H. Generic antiepileptic drugs — safe or harmful in patients with epilepsy? Epilepsia 59, 1273–1281 (2018).

    Article  Google Scholar 

Download references

Acknowledgements

The author holds the Friedrich-von-Bodelschwingh Endowed Professorship for Clinical and Experimental Epileptology at the Department of Neurology, Charité–Universitätsmedizin Berlin funded by the v. Bodelschwingh Foundation. The funder had no influence on this work.

Author information

Affiliations

  1. Epilepsy-Center Berlin-Brandenburg, Department of Neurology, Charité — Universitätsmedizin Berlin, Berlin, Germany

    Martin Holtkamp

Authors
  1. Martin Holtkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Holtkamp.

Ethics declarations

Competing interests

The author has received speaker’s honoraria and/or consultancy fees from Bial, Desitin, Eisai, LivaNova, Novartis and UCB.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Holtkamp, M. How safe is switching antiepileptic drug manufacturers?. Nat Rev Neurol 15, 8–9 (2019). https://doi.org/10.1038/s41582-018-0108-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-018-0108-6

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing